Ilson, David

Publications

Sort by

Co-Author Network

selected publications

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 188
Advances in the treatment of gastric cancer: 2019. Current opinion in gastroenterology. 2019 Review GET IT
Times cited: 33
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The oncologist. 2019 Academic Article GET IT
Times cited: 9
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?. Annals of surgery. 2019 Letter GET IT
Times cited: 2
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 10
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 162
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer discovery. 2018 Academic Article GET IT
Times cited: 98
Advances in the treatment of gastric cancer. Current opinion in gastroenterology. 2018 Review GET IT
Times cited: 52
Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert review of anticancer therapy. 2018 Review GET IT
Times cited: 7
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018 Academic Article GET IT
Times cited: 14
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 214
Advances in the treatment of gastric cancer. Current opinion in gastroenterology. 2017 Review GET IT
Times cited: 34
The role of radiation therapy in upper gastrointestinal cancers. Clinical advances in hematology & oncology : H&O. 2017 Review GET IT
Times cited: 4
Current Progress in the Adjuvant Treatment of Gastric Cancer. Surgical oncology clinics of North America. 2017 Review GET IT
Times cited: 13
Updates in Esophagogastric Cancer. Surgical oncology clinics of North America. 2017 Editorial Article GET IT
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 22
An update in the nonendoscopic treatment of gastric cancer. Current opinion in gastroenterology. 2016 Review GET IT
Times cited: 1
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. 2016 GET IT
Times cited: 660
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016 Academic Article GET IT
Times cited: 21
Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 61
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 68
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Academic Article GET IT
Times cited: 26
Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Times cited: 6
Patterns and Predictors of Weight Loss After Gastrectomy for Cancer. Annals of surgical oncology. 2016 Academic Article GET IT
Times cited: 44
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British journal of cancer. 2015 Academic Article GET IT
Times cited: 15
Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Comment GET IT
Times cited: 7
Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Academic Article GET IT
Times cited: 65
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PloS one. 2015 Academic Article GET IT
Times cited: 35
Esophageal and esophagogastric junction cancers, version 1.2015. 2015 GET IT
Times cited: 294
Emerging mAbs for the treatment of esophagogastric cancer. Expert opinion on emerging drugs. 2014 Review GET IT
Times cited: 1
Management of gastric cancer. Current opinion in gastroenterology. 2014 Review GET IT
Times cited: 18
Esophageal reinforcement with an extracellular scaffold during total gastrectomy for gastric cancer. Annals of surgical oncology. 2014 Academic Article GET IT
Times cited: 20
HER2 directed therapy for gastric/esophageal cancers. Current treatment options in oncology. 2014 Review GET IT
Times cited: 20
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. American journal of clinical oncology. 2014 Academic Article GET IT
Times cited: 7
Management of localized esophageal cancer in the older patient. The oncologist. 2014 Review GET IT
Times cited: 36
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Annals of surgical oncology. 2013 Academic Article GET IT
Times cited: 22
Adjuvant (postoperative) therapy for esophageal cancer. Thoracic surgery clinics. 2013 Review GET IT
Times cited: 13
Angiogenesis in gastric cancer: hitting the target?. Lancet (London, England). 2013 Comment GET IT
Times cited: 27
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2013 Review GET IT
Times cited: 96
Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2013 Academic Article GET IT
Times cited: 27
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma. Gastrointestinal cancer research : GCR. 2013 Academic Article GET IT
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2013 Academic Article GET IT
Times cited: 8
Emerging tyrosine kinase inhibitors for esophageal cancer. Expert opinion on emerging drugs. 2013 Review GET IT
Times cited: 11
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. 2013 GET IT
Times cited: 413
Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. Brachytherapy. 2013 Academic Article GET IT
Times cited: 17
Chemotherapeutic options for gastroesophageal junction tumors. Seminars in radiation oncology. 2013 Review GET IT
Times cited: 8
Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET-CT useful?. Clinical imaging. 2012 Academic Article GET IT
Times cited: 7
Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointestinal cancer research : GCR. 2012 Academic Article GET IT
Times cited: 63
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2011 Academic Article GET IT
Times cited: 64
Barrett's esophagus: treatments of adenocarcinomas II. Annals of the New York Academy of Sciences. 2011 Academic Article GET IT
Times cited: 1
Esophageal and esophagogastric junction cancers. 2011 GET IT
Times cited: 175
Modern approaches to localized cancer of the esophagus. Journal of the National Comprehensive Cancer Network : JNCCN. 2011 Academic Article GET IT
Times cited: 9
Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. Cancer. 2011 Academic Article GET IT
Times cited: 12
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. British journal of cancer. 2011 Academic Article GET IT
Times cited: 85
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 174
Preoperative therapy in esophageal cancer: controversy and consensus. Oncology (Williston Park, N.Y.). 2010 Comment GET IT
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2010 Academic Article GET IT
Times cited: 87
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 44
Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan. 2010 GET IT
Times cited: 8
Gastric cancer. 2010 GET IT
Times cited: 133
Esophagogastric cancer: targeted agents. Cancer treatment reviews. 2010 Review GET IT
Times cited: 51
Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Therapeutic advances in medical oncology. 2009 Academic Article GET IT
Times cited: 6
Upper gastrointestinal malignancies: a new era in clinical colorectal cancer. Clinical colorectal cancer. 2009 Editorial Article GET IT
Times cited: 1
Stage IV small bowel carcinoma mimicking advanced ovarian cancer. The American surgeon. 2009 Letter GET IT
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Academic Article GET IT
Times cited: 72
Role of neoadjuvant therapy for esophageal adenocarcinoma. Surgical oncology clinics of North America. 2009 Review GET IT
Times cited: 11
NCCN task force: clinical utility of PET in a variety of tumor types. Journal of the National Comprehensive Cancer Network : JNCCN. 2009 Review GET IT
Times cited: 93
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation. 2009 Academic Article GET IT
Times cited: 1
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Annals of surgery. 2009 Academic Article GET IT
Times cited: 80
Preoperative therapy for esophageal cancer. Gastroenterology clinics of North America. 2009 Academic Article GET IT
Times cited: 12
Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy. 2009 GET IT
Times cited: 9
Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert review of anticancer therapy. 2008 Review GET IT
Times cited: 3
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Investigational new drugs. 2008 Academic Article GET IT
Times cited: 4
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. European journal of cancer (Oxford, England : 1990). 2008 Conference Paper GET IT
Times cited: 37
Preoperative therapy in esophageal cancer. Clinical advances in hematology & oncology : H&O. 2008 Review GET IT
Times cited: 6
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer chemotherapy and pharmacology. 2008 Academic Article GET IT
Times cited: 42
Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 33
Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 95
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Editorial Article GET IT
Times cited: 49
Combined modality chemoradiation in elderly oesophageal cancer patients. British journal of cancer. 2007 Academic Article GET IT
Times cited: 61
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Letter GET IT
Times cited: 16
Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Editorial Article GET IT
Times cited: 6
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 73
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 163
Esophageal cancer: adjuvant therapy. Cancer journal (Sudbury, Mass.). 2007 Review GET IT
Times cited: 13
Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome. Leukemia & lymphoma. 2007 Letter GET IT
Times cited: 1
Targeted agents and esophageal cancer--the next step?. Seminars in radiation oncology. 2007 Review GET IT
Times cited: 23
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 412
Cancer of the gastroesophageal junction: combined modality therapy. Surgical oncology clinics of North America. 2006 Review GET IT
Times cited: 15
Cancer of the gastroesophageal junction: Current therapy options. Current treatment options in oncology. 2006 Review GET IT
Times cited: 8
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 26
Esophageal Cancer Clinical Practice Guidelines. 2006 GET IT
Times cited: 25
Gastric Cancer Clinical Practice Guidelines. 2006 GET IT
Times cited: 25
Just when you thought the fluorouracil debate was over: S-1 and gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Editorial Article GET IT
Times cited: 5
Targeted therapies for esophageal cancer. The oncologist. 2005 Review GET IT
Times cited: 139
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Letter GET IT
Times cited: 117
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 104
Pelvic CT in patients with esophageal cancer. AJR. American journal of roentgenology. 2005 Academic Article GET IT
Times cited: 13
Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park, N.Y.). 2004 Academic Article GET IT
Times cited: 38
New advances in the treatment of gastric cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Treatment of localized esophageal cancer. Seminars in oncology. 2004 Review GET IT
Times cited: 48
New developments in the treatment of esophageal cancer. Clinical advances in hematology & oncology : H&O. 2004 Review GET IT
Times cited: 8
Editorial on a phase I study on combined modality therapy in esophageal cancer. Cancer investigation. 2004 Editorial Article GET IT
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 66
Oesophageal cancer: new developments in systemic therapy. Cancer treatment reviews. 2003 Review GET IT
Times cited: 61
Irinotecan in esophageal cancer. Oncology (Williston Park, N.Y.). 2003 Academic Article GET IT
Times cited: 9
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 91
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 312
Combined modality therapy in esophageal cancer: the Memorial experience. Seminars in surgical oncology. 2003 Academic Article GET IT
Times cited: 17
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer investigation. 2003 Academic Article GET IT
Times cited: 21
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Annals of surgical oncology. 2002 Academic Article GET IT
Times cited: 58
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. The Journal of thoracic and cardiovascular surgery. 2002 Academic Article GET IT
Times cited: 73
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Academic Article GET IT
Times cited: 97
Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 14
New developments in the treatment of esophageal cancer. Current oncology reports. 2002 Review GET IT
Times cited: 9
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Editorial Article GET IT
Times cited: 15
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 147
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 19
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Annals of surgical oncology. 2001 Academic Article GET IT
Times cited: 109
Adjuvant therapy for noncolorectal cancers. Current opinion in oncology. 2001 Review GET IT
Times cited: 5
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 201
Cisplatin and irinotecan in upper gastrointestinal malignancies. Oncology (Williston Park, N.Y.). 2001 Review GET IT
Times cited: 4
Irinotecan in esophageal cancer. Oncology (Williston Park, N.Y.). 2000 Review GET IT
Times cited: 13
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. Journal of the National Cancer Institute. 2000 Academic Article GET IT
Times cited: 331
A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer journal (Sudbury, Mass.). 2000 Academic Article GET IT
Times cited: 119
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999 Academic Article GET IT
Times cited: 335
Chemotherapy in esophageal cancer. Seminars in oncology. 1999 Review GET IT
Times cited: 135
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 248
Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. Cancer. 1999 Academic Article GET IT
Times cited: 13
A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer investigation. 1999 Academic Article GET IT
Times cited: 25
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 44
Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology (Williston Park, N.Y.). 1998 Review GET IT
Times cited: 18
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 189
Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer investigation. 1998 Academic Article GET IT
Times cited: 102
A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. American journal of clinical oncology. 1997 Academic Article GET IT
Times cited: 15
A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 29
Neoadjuvant therapy of esophageal cancer. Surgical oncology clinics of North America. 1997 Review GET IT
Times cited: 24
Toxicity of chemotherapy for esophageal carcinoma. Chest surgery clinics of North America. 1997 Review GET IT
Times cited: 4
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Diseases of the colon and rectum. 1997 Academic Article GET IT
Times cited: 240
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. International journal of radiation oncology, biology, physics. 1997 Academic Article GET IT
Times cited: 159
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Seminars in oncology. 1996 Academic Article GET IT
Times cited: 14
Management of esophageal cancer. Oncology (Williston Park, N.Y.). 1996 Review GET IT
Times cited: 15
The activity of paclitaxel in gastrointestinal tumors. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 17
Chemotherapy and combined-modality therapy for esophageal cancer. Chest. 1995 Review GET IT
Times cited: 34
Paclitaxel in the treatment of carcinoma of the esophagus. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 26
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer. 1995 Academic Article GET IT
Times cited: 32
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Seminars in oncology. 1994 Academic Article GET IT
Times cited: 14
Combined modality therapy in the treatment of esophageal cancer. Seminars in oncology. 1994 Review GET IT
Times cited: 75
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. Journal of the National Cancer Institute. 1994 Academic Article GET IT
Times cited: 259
Adjuvant postoperative therapy of gastrointestinal malignancies. Oncology (Williston Park, N.Y.). 1994 Review GET IT
Times cited: 2
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. Journal of the National Cancer Institute. 1994 Academic Article GET IT
Times cited: 114
Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer. 1994 Academic Article GET IT
Times cited: 128
Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. Journal of the National Cancer Institute. 1994 Academic Article GET IT
Times cited: 47
Phase II trial of topotecan in patients with advanced renal cell carcinoma. Investigational new drugs. 1994 Academic Article GET IT
Times cited: 35
Chemotherapy in esophageal cancer. Anti-cancer drugs. 1993 Review GET IT
Times cited: 11
Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Seminars in oncology. 1993 Review GET IT
Times cited: 40
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 70
Genetic analysis of germ cell tumors: current progress and future prospects. Hematology/oncology clinics of North America. 1991 Review GET IT
Times cited: 14
Two molecular weight forms of human 2',5'-oligoadenylate synthetase have different activation requirements. Journal of interferon research. 1986 Academic Article GET IT
Times cited: 19

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 1986
Ph.D., New York University 1985
M.S., New York University 1984
B.S., University of Connecticut 1979

Contact

full name

David Ilson

VIVO Weill Cornell Medical College

David Ilson Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name